Approval of Composite Scheme of Arrangement by NCLT
As filed · Sun Pharmaceutical Industries Limited has informed the Exchange about Approval of Composite Scheme of Arrangement by NCLT
What happened
FactSun Pharmaceutical Industries Limited has informed the Exchange about Approval of Composite Scheme of Arrangement by NCLT. Regulations, 2015 – NCLT approves the Composite Scheme of Arrangement. 7 October 2025 (which is made available on the NCLT portal today, i.e.
Why it matters
CapitSignal interpretationOnce an insolvency process is admitted, control of the company passes from the board to a resolution professional and equity ranks last in any recovery.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnWe believe this transaction positions Sun Pharma well for long-term sustainable growth and value creation.
we do not give forward guidance for any particular, you should look at our overall revenue growth guidance that we have given for the year for the company.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Admission or rejection of the application by the tribunal
- Appointment of a resolution professional
- Claims admitted against the company
- Target mid to high single digit consolidated topline growth for FY26 (management committed by FY26)
Evidence
- Sun Pharmaceutical Industries Limited has informed the Exchange about Approval of Composite Scheme of Arrangement by NCLT(opens the original filing in a new tab)
- Earlier statement · FY26
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- INSOLVENCY base 93; explicit insolvency/default evidence present; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%